Psychopharm Today

Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.

Andrew A. Nierenberg, MD, explains how the Bipolar Action Network uses shared data and improvement science to change how bipolar disorder care is delivered.

Maurizio Fava, MD, discusses treatment-resistant depression, the placebo response, ketamine research, mentorship, and where AI fits into psychiatry's future.

Learn insights from an early investigator of treatment-resistant depression and expert in the field.

Entactogen research targets social anxiety and isolation across diagnoses, pairing “plasticity windows” with psychotherapy amid shifting FDA scrutiny and evolving trial designs.

Experts weigh MDMA-like entactogens for social anxiety and depression, neuroplasticity windows, and what FDA setbacks mean for next-wave treatments.

Experts urge metabolic screening across psychiatric diagnoses, spotlighting tailored interventions and tools like PsyMetRiC—while warning risk talks can backfire.

Experts explain why every diagnosis needs metabolic screening, how to discuss risk safely, and when to use tools like PsyMetRiC to assess risk.

In this inaugural episode, experts discuss the limitations of current diagnosis-based frameworks in suicide research, emphasizing the need for more targeted interventions.

In the first ever episode of "Psychopharm Today," experts unpack why suicide needs its own research, how to design targeted studies, and what clinicians can do beyond diagnosis to reduce risk.